Submitted:
18 March 2025
Posted:
18 March 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
Prevalence of H. pylori Infection
Chronic Gastrointestinal Conditions
Symptoms Associated with H. pylori Infection
Histopathological Findings
Statistical Analysis of Gastrointestinal Complications
4. Discussion
5. Conclusion
Supplementary Materials
Author Contributions
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024;166(4):605-19. [CrossRef]
- Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19.
- Carrasco G, Corvalan AH. Helicobacter pylori-Induced Chronic Gastritis and Assessing Risks for Gastric Cancer. Gastroenterol Res Pract. 2013;2013:393015. [CrossRef]
- Schöttker B, Adamu MA, Weck MN, Brenner H. Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. Clin Gastroenterol Hepatol. 2012;10(5):487-93.e1. [CrossRef]
- Emmanuel BN, Peter DA, Peter MO, Adedayo IS, Olaifa K. Helicobacter pylori infection in Africa: comprehensive insight into its pathogenesis, management, and future perspectives. Journal of UmmAl-Qura University for Applied Sciences. 2024. [CrossRef]
- Ibrahim ME. Epidemiology, pathogenicity, risk factors, and management of Helicobacter pylori infection in Saudi Arabia. Biomol Biomed. 2024;24(3):440-53. [CrossRef]
- Alsulaimany FAS, Awan ZA, Almohamady AM, Koumu MI, Yaghmoor BE, Elhady SS, et al. Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region. Medicina (Kaunas). 2020;56(4). [CrossRef]
- Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, et al. Extra-Gastric Manifestations of Helicobacter pylori Infection. Journal of Clinical Medicine [Internet]. 2020; 9(12). [CrossRef]
- Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: Extragastric diseases and Helicobacter pylori. Helicobacter. 2020;25 Suppl 1:e12741. [CrossRef]
- Schistosomes I. liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
- Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's gastrointestinal and liver disease E-book: pathophysiology, diagnosis, management: Elsevier health sciences; 2020.
- Costa LCMC, das Graças Carvalho M, La Guárdia Custódio Pereira AC, Teixeira Neto RG, Andrade Figueiredo LC, Barros-Pinheiro M. Diagnostic Methods for Helicobacter pylori. Medical Principles and Practice. 2024;33(3):173-84. [CrossRef]
- Nakashima H, Kawahira H, Kawachi H, Sakaki N. Artificial intelligence diagnosis of Helicobacter pylori infection using blue laser imaging-bright and linked color imaging: a single-center prospective study. Ann Gastroenterol. 2018;31(4):462-8.
- Woodward M, Morrison C, McColl K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol. 2000 Feb;53(2):175-81. [CrossRef] [PubMed]
- Yang Y-J, Yang H-B, Wu J-J, Sheu B-S. Persistent H. pylori colonization in early acquisition age of mice related with higher gastric sialylated Lewis x, IL-10, but lower interferon-γ expressions. Journal of Biomedical Science. 2008;16(1):34.
- Moayyedi P, Forman D, Braunholtz D, Feltbower R, Crocombe W, Liptrott M, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group. Am J Gastroenterol. 2000;95(6):1448-55.
- Loosen SH, Mertens A, Klein I, Leyh C, Krieg S, Kandler J, et al. Association between Helicobacter pylori and its eradication and the development of cancer. BMJ Open Gastroenterol. 2024;11(1).
- Toh JWT, Wilson RB. Pathways of Gastric Carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals. Int J Mol Sci. 2020;21(17).
- He, S., He, X., Duan, Y. et al. The impact of diet, exercise, and sleep on Helicobacter pylori infection with different occupations: a cross-sectional study. BMC Infect Dis 24, 692 (2024). [CrossRef]
- Elhariri, M., Hamza, D., Elhelw, R. et al. Occurrence of cagA+ vacA s1a m1 i1 Helicobacter pylori in farm animals in Egypt and ability to survive in experimentally contaminated UHT milk. Sci Rep 8, 14260 (2018). [CrossRef]
- Amaral O, Fernandes I, Veiga N, Pereira C, Chaves C, Nelas P, et al. Living Conditions and Helicobacter pylori in Adults. Biomed Res Int. 2017;2017:9082716. [CrossRef]
- Gisbert JP, Calvet X. Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. Clin Transl Gastroenterol. 2013;4(3):e32. [CrossRef]
- Luan X, Niu P, Wang W, Zhao L, Zhang X, Zhao D, et al. Sex Disparity in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. J Oncol. 2022;2022:1269435. [CrossRef]
- Arakawa H, Komatsu S, Kamiya H, Nishibeppu K, Ohashi T, Konishi H, et al. Differences of clinical features and outcomes between male and female elderly patients in gastric cancer. Scientific Reports. 2023;13(1):17192. [CrossRef]
- Jencks DS, Adam JD, Borum ML, Koh JM, Stephen S, Doman DB. Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer. Gastroenterol Hepatol (N Y). 2018;14(2):92-101.
- Graham DY, Lu H, Yamaoka Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. J Dig Dis. 2009;10(2):77-84.
- Bustos-Fraga S, Salinas-Pinta M, Vicuña-Almeida Y, de Oliveira RB, Baldeón-Rojas L. Prevalence of Helicobacter pylori genotypes: cagA, vacA (m1), vacA (s1), babA2, dupA, iceA1, oipA and their association with gastrointestinal diseases. A cross-sectional study in Quito-Ecuador. BMC Gastroenterology. 2023;23(1):197. [CrossRef]
- Datta De D, Roychoudhury S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J Gastroenterol. 2015;21(10):2883-95.
- Roesler BM, Rabelo-Gonçalves EM, Zeitune JM. Virulence Factors of Helicobacter pylori: A Review. Clin Med Insights Gastroenterol. 2014;7:9-17. [CrossRef]
- Cavadas B, Leite M, Pedro N, Magalhães AC, Melo J, Correia M, et al. Shedding Light on the African Enigma: In Vitro Testing of Homo sapiens-Helicobacter pylori Coevolution. Microorganisms [Internet]. 2021; 9(2). [CrossRef]
- Di J, Ge Z, Xie Q, Kong D, Liu S, Wang P, Li J, Ning N, Qu W, Guo R, Chang D, Zhang J, Zheng XH. Helicobacter pylori infection increases the risk of thyroid nodules in adults of Northwest China. Front Cell Infect Microbiol. 2023 Mar 31;13:1134520. [CrossRef] [PubMed] [PubMed Central]


| Variable | Gender | Age (years) | N (%) |
| H. pylori Bacteria | Male (n=329) | 20-39 | No: 31 (12.9%) |
| Yes: 209 (87.1%) | |||
| 40-59 | No: 5 (5.8%) | ||
| Yes: 81 (94.2%) | |||
| 60-80 | No: 0 (0.0%) | ||
| Yes: 3 (100.0%) | |||
| Female (n=476) | 20-39 | No: 29 (8.1%) | |
| Yes: 329 (91.9%) | |||
| 40-59 | No: 13 (11.0%) | ||
| Yes: 105 (89.0%) | |||
| 60-80 | No: 0 (0.0%) | ||
| Yes: 0 (0.0%) | |||
| Chronic Diseases | Gastrointestinal Complications | No: 1 (0.1%) | |
| Yes: 726 (99.9%) | |||
| Lymphoma | No: 726 (99.9%) | ||
| Yes: 1 (0.1%) | |||
| Metaplasia | No: 721 (99.2%) | ||
| Yes: 6 (0.8%) | |||
| Chronic Gastritis | No: 587 (80.7%) | ||
| Yes: 140 (19.3%) | |||
| Atrophy | No: 725 (99.7%) | ||
| Yes: 2 (0.3%) | |||
| Gastric Lipoma | No: 721 (99.2%) | ||
| Yes: 6 (0.8%) | |||
| Gastric Polyp | No: 722 (99.3%) | ||
| Yes: 5 (0.7%) | |||
| Gender | Chronic gastritis (No) | Chronic gastritis (Yes) | Total | Risk Estimate | Value | 95% Confidence Interval (Lower) | 95% Confidence Interval (Upper) |
|---|---|---|---|---|---|---|---|
| Male | 268 | 61 | 329 | Odds Ratio for Gender (Male / Female) | 0.888 | 0.615 | 1.282 |
| Female | 396 | 80 | 476 | For Cohort Chronic gastritis = No | 0.979 | 0.917 | 1.045 |
| Total | 664 | 141 | 805 | For Cohort Chronic gastritis = Yes | 1.103 | 0.816 | 1.492 |
| N of Valid Cases | 805 |
| Gender | H. pylori (No) | H. pylori (Yes) | Total | Risk Estimate | Value | 95% Confidence Interval (Lower) | 95% Confidence Interval (Upper) |
|---|---|---|---|---|---|---|---|
| Male | 36 | 293 | 329 | Odds Ratio for Gender (Male / Female) | 1.270 | 0.794 | 2.030 |
| Female | 42 | 434 | 476 | For Cohort H. pylori = No | 1.240 | 0.813 | 1.892 |
| Total | 78 | 727 | 805 | For Cohort H. pylori = Yes | 0.977 | 0.932 | 1.024 |
| N of Valid Cases | 805 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).